-
公开(公告)号：US20070077239A1
公开(公告)日：2007-04-05
申请号：US11514578
申请日：2006-09-01
CPC分类号： A61K48/0008 , A61K38/00 , A61K47/62 , A61K47/66 , B82Y5/00 , C12N9/0065
摘要： The present invention is directed to compositions based on myeloperoxidase amino acid sequence which may be used as therapeutic agents or as delivery vehicles for the delivery of other therapeutic agents.
摘要翻译： 本发明涉及可用作治疗剂或作为递送其它治疗剂的递送载体的基于髓过氧化物酶氨基酸序列的组合物。
-
公开(公告)号：US20060229266A1
公开(公告)日：2006-10-12
申请号：US10567958
申请日：2004-08-10
申请人： Nalin Kumar , Beatrice Yue , Shahid Siddiqui , Asrar Malik , Jose Pulido
发明人： Nalin Kumar , Beatrice Yue , Shahid Siddiqui , Asrar Malik , Jose Pulido
CPC分类号： C12N15/1138 , C12N2310/14
摘要： The present application is directed to siRNA-based silencing of the type II receptor of TGFβ. siRNAs that target this receptor abrogate the receptor protein and transcript, TGFβ-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory response and matrix deposition. These findings show that siRNAs can be successfully delivered both in vitro and in vivo to regulate the TGFβ type II receptor level and modulate wound response. Methods and compositions exploiting the findings of the present invention have a wide-ranging application, extending from treatment of disorders of the eye to other organs and tissues throughout the body.
摘要翻译： 本申请涉及TGFbeta的II型受体的基于siRNA的沉默。 靶向该受体的siRNA消除受体蛋白和转录物，TGFβ介导的过程如纤连蛋白装配和细胞迁移也受到抑制，本发明的分子有效降低炎症反应和基质沉积。 这些研究结果表明siRNA可以在体外和体内成功递送，以调节TGFbeta II型受体水平并调节伤口应答。 利用本发明的发现的方法和组合物具有广泛的应用，从眼睛疾病的治疗延伸到整个身体的其他器官和组织。
-
公开(公告)号：US07825101B2
公开(公告)日：2010-11-02
申请号：US12439370
申请日：2007-08-30
申请人： Dolly Mehta , Shahid S. Siddiqui , Asrar Malik
发明人： Dolly Mehta , Shahid S. Siddiqui , Asrar Malik
CPC分类号： C12N15/1137 , C12N2310/14 , C12Y207/11018
摘要： In various aspects and embodiments the invention provides methods and reagents for controlling gene expression, and for treating disorders and diseases. Embodiments provide methods and reagents specifically for the regulation of MLCK expression and for the use thereof in treating disorders and diseases. Various embodiments provide methods and reagents for specifically down regulating the expression of MLCK-L more efficiently than that of MLCK-S, and for the use thereof in treating disorders and diseases. Embodiments provide siNA for the same, particularly siRNAs. Various of the embodiments are useful for the treatment of inflammatory disorders and diseases, including, for one example in this regard, Asthma.
摘要翻译： 在各方面和实施方案中，本发明提供了用于控制基因表达和用于治疗疾病和疾病的方法和试剂。 实施方案提供专门用于调节MLCK表达的方法和试剂以及用于治疗疾病和疾病的方法和试剂。 各种实施方案提供了比MLCK-S更有效地特异性地下调MLCK-L的表达的方法和试剂，以及用于治疗疾病和疾病的方法和试剂。 实施方案提供了相同的siRNA，特别是siRNA的siNA。 各种实施方案可用于治疗炎症性疾病和疾病，包括在这方面的一个实例，哮喘。
-
公开(公告)号：US20080160552A1
公开(公告)日：2008-07-03
申请号：US11954933
申请日：2007-12-12
申请人： Dolly Mehta , Nebojsa Knezevic , Asrar Malik
发明人： Dolly Mehta , Nebojsa Knezevic , Asrar Malik
CPC分类号： A61K31/47 , G01N33/5041 , G01N2333/914
摘要： The invention relates in embodiments to methods for identifying compounds that inhibit phosphorylation of GD-1, to compositions comprising such inhibitors, including pharmaceutical compositions, and to the use of such inhibitors and compositions to treat diseases, such as inflammatory diseases.
摘要翻译： 本发明在实施方案中涉及用于鉴定抑制GD-1磷酸化的化合物的方法，包括包含药物组合物的这种抑制剂的组合物，以及这些抑制剂和组合物用于治疗诸如炎性疾病的疾病的用途。
-
公开(公告)号：US20100093830A1
公开(公告)日：2010-04-15
申请号：US12439370
申请日：2007-08-30
申请人： Dolly Mehta , Shahid S. Siddiqui , Asrar Malik
发明人： Dolly Mehta , Shahid S. Siddiqui , Asrar Malik
IPC分类号： A61K31/7105 , C07H21/02 , C12N5/00 , A61P11/06 , A61P29/00
CPC分类号： C12N15/1137 , C12N2310/14 , C12Y207/11018
摘要： In various aspects and embodiments the invention provides methods and reagents for controlling gene expression, and for treating disorders and diseases. Embodiments provide methods and reagents specifically for the regulation of MLCK expression and for the use thereof in treating disorders and diseases. Various embodiments provide methods and reagents for specifically down regulating the expression of MLCK-L more efficiently than that of MLCK-S, and for the use thereof in treating disorders and diseases. Embodiments provide siNA for the same, particularly siRNAs. Various of the embodiments are useful for the treatment of inflammatory disorders and diseases, including, for one example in this regard, Asthma.
摘要翻译： 在各方面和实施方案中，本发明提供了用于控制基因表达和用于治疗疾病和疾病的方法和试剂。 实施方案提供专门用于调节MLCK表达的方法和试剂以及用于治疗疾病和疾病的方法和试剂。 各种实施方案提供了比MLCK-S更有效地特异性地下调MLCK-L的表达的方法和试剂，以及用于治疗疾病和疾病的方法和试剂。 实施方案提供了相同的siRNA，特别是siRNA的siNA。 各种实施方案可用于治疗炎症性疾病和疾病，包括在这方面的一个实例，哮喘。
-
-
-
-
搜索结果
5 条记录 (耗时 0.015 秒)
